U.S., Jan. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07340723) titled 'Novel First-line Therapies for Grade II Acute GVHD(Graft-versus-host Disease )' on Jan. 05.
Brief Summary: The purpose of this study is to determine the efficacy and safety of combined Ruxolitinib With Corticosteroids as First Line Therapy for grade II acute GVHD (graft-versus-host disease )
Study Start Date: June 01, 2025
Study Type: INTERVENTIONAL
Condition:
GVHD,Acute
Stem Cell Transplant Complications
Intervention:
DRUG: Ruxolitinib
Participants began oral administration of ruxolitinib at 5 mg QD;Methylprednisolone: 0.5mg/kg/d , iv or iv gtt for at least 5 days, then taper according to the clinical response.
DRUG: Cortic...